"Our partnership with PathoQuest represents a significant step forward in our commitment to empower tomorrow’s therapies today. PathoQuest’s expertise in NGS technology will greatly enhance our capabilities and allow us to deliver even greater value to our clients through our comprehensive viral vector services, from process development to cGMP manufacturing for clinical and commercial supply."

Robert Panting
General Manager
Rentschler Biopharma, ATMP

"IAVI has chosen to work with PathoQuest as the iDTECT Virome approach has permitted us to adopt next generation sequencing (NGS) for viral safety testing, replacing the traditional in vivo and in vitro testing for the release of our vaccine vectors in a safe and timely manner. We also appreciate their virology expertise in trouble-shooting and problem-solving for safety testing of our viral vectors."

Eddy Sayeed
Executive Director, Process Development & Vaccine Manufacturing/Vaccine
IAVI

"We have been impressed by PathoQuest’s excellent service. They supported us with their NGS-based Quality Control platform, enabling us to navigate technical and regulatory hurdles to reach a key milestone. PathoQuest has been a reliable and trustworthy partner for biosafety testing."

Jack Elands, PhD
Former Chief Executive Officer
Emergence Therapeutics AG (recently acquired by Eli Lilly)

"We chose PathoQuest NGS viral safety tests for rapid and reliable Quality Control of our therapeutic cancer vaccine in development, ensuring batch release in weeks instead of months"

Christophe Ancel, PharmD
V.P. Pharmaceutical Operations & Qualified Person
Transgene SA

"Our collaboration with PathoQuest is helping our customers overcoming the limitations of traditional QC methods. As a CDMO, using PathoQuest's NGS assays, we can advance our customers projects safely, while ensuring timelines are met."

Nicolas Salavin
Head of Transformation & Integration
Oxford Biomedica (CDMO)